Karimov Jamshid H, Dessoffy Raymond, Kobayashi Mariko, Dudzinski David T, Klatte Ryan S, Kattar Jacqueline, Moazami Nader, Fukamachi Kiyotaka
Department of Biomedical Engineering, Lerner Research Institute, Cleveland Clinic, Cleveland, OH, USA.
Medical Device Solutions, Lerner Research Institute, Cleveland Clinic, Cleveland, OH, USA.
Interact Cardiovasc Thorac Surg. 2014 Jul;19(1):1-5. doi: 10.1093/icvts/ivu089. Epub 2014 Apr 7.
We designed a device that applies motion-activated energy (vibration) to prevent chest-tube clogging and maintain tube patency. We evaluated the efficacy of this device in vitro and in vivo.
The motion-activated system (MAS) device assembly comprises a direct current motor with an eccentric mass (3.2 g, centroid radius of 4.53 mm) affixed to its motor shaft. The device was tested in vitro using a model of an obstructed chest tube, with clots of bovine blood and human thrombin. The in vivo study (in nine healthy pigs, 46.0 ± 3.3 kg) involved a bilateral minithoracotomy and placement of 32-Fr chest tubes (with and without the device). Whole autologous blood (120 ml) was injected every 15 min into the right and left chest each over 120 min total.
Chest-tube drainage over these 2 h using the MAS was significantly higher than that without the device (369 ± 113 ml vs 209 ± 115 ml; P = 0.027).
Our results suggest that the motion-activation of the chest tubes may be an effective tool to maintain chest tubes patent. Further optimization of this technology is required to obtain more consistent prevention of clot deposition within or outside the chest tubes.
我们设计了一种利用运动激活能量（振动）的装置，以防止胸管堵塞并保持管道通畅。我们在体外和体内评估了该装置的功效。
运动激活系统（MAS）装置组件包括一个直流电机，其电机轴上固定有一个偏心质量块（3.2克，质心半径4.53毫米）。该装置在体外使用阻塞胸管模型、牛血凝块和人凝血酶进行测试。体内研究（在9头健康猪中进行，体重46.0±3.3千克）包括双侧小开胸术和放置32F胸管（有或无该装置）。每15分钟向左右胸腔各注入120毫升全自体血，共注入120分钟。
使用MAS在这2小时内的胸管引流量显著高于未使用该装置的情况（369±113毫升对209±115毫升；P=0.027）。
我们的结果表明，胸管的运动激活可能是保持胸管通畅的有效工具。需要对该技术进行进一步优化，以更一致地防止胸管内外形成凝块沉积。
